Olipass Corp

244460

Company Profile

  • Business description

    Olipass Corp is a South Korea based biotechnology company engaged in developing its platform OliPass PNA which focuses on introducing cationic lipid moiety onto nucleobase. Its pipeline products include SC Injection, Hyper Cholesterolemia, Chemo/Radio-sensitizer, and Type II Diabetes among others.

  • Contact

    16-4, 16 Beon-gil, Dongbaek Jungang-ro
    Ace Dongbaek Tower 20th Floor
    Giheung-gu
    Yongin17015
    KOR

    T: +82 3180608200

    https://www.olipass.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    39

Stocks News & Analysis

stocks

After earnings, is Alphabet stock a buy, a sell, or fairly valued?

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks

Moated ASX share crashes amid weak trading update

Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,015.4048.700.54%
CAC 407,861.964.600.06%
DAX 4024,262.2244.850.19%
Dow JONES (US)44,343.88289.11-0.65%
FTSE 1009,136.940.620.01%
HKSE25,176.93347.52-1.36%
NASDAQ21,071.6426.65-0.13%
Nikkei 22540,654.7019.85-0.05%
NZX 50 Index12,855.9780.44-0.62%
S&P 5006,348.1222.74-0.36%
S&P/ASX 2008,756.4051.800.60%
SSE Composite Index3,615.726.010.17%

Market Movers